The Goldman Sachs Group Initiates Coverage on Silence Therapeutics (NASDAQ:SLN)
Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s price objective would indicate […]
Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “sell” rating and a $6.00 price target on the stock. The Goldman Sachs Group’s price objective would indicate […]
